Literature DB >> 8080010

Long-term renal effect of cisplatin in man.

G Brillet1, G Deray, C Jacquiaud, L Mignot, D Bunker, D Meillet, F Raymond, C Jacobs.   

Abstract

Although the acute nephrotoxicity of cisplatin has been well documented, long-term follow-up studies are scanty. We have evaluated the renal function in 35 patients who have had completed therapy with cisplatin at least 3 months before the study. All patients had normal serum creatinine levels before chemotherapy. Evaluation of renal function included: serum creatinine, glomerular filtration rate (inulin clearance), effective renal plasma flow (p-aminohippurate clearance), urinary beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase excretion, and renal tomography. The median cumulated dose of cisplatin was 603 +/- 37 mg/m2. The mean serum creatinine level was 78 +/- 21 and 88 +/- 3 mumol/l before and after chemotherapy, respectively (p < 0.05). Mean glomerular filtration rate (92 +/- 4 ml/min) and effective renal plasma flow (362 +/- 21 ml/min) were significantly lower than in controls (110 +/- 3 and 436 +/- 24 ml/min). The mean enzymuria and the renal size remained within the normal range. In 12 patients who were reevaluated 12 and 24 months later, glomerular filtration rate and effective renal plasma flow remained stable. These results suggest that at usual dosages cisplatin is associated with a nonprogressive loss of renal function which is of a moderate degree.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080010     DOI: 10.1159/000168693

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  14 in total

1.  Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.

Authors:  Thana Patimarattananan; Arkom Nongnuch; Poompis Pattaranutaporn; Nattawut Unwanatham; Chuleeporn Jiarpinitnun; Nuttapong Ngamphaiboon
Journal:  Support Care Cancer       Date:  2020-06-10       Impact factor: 3.603

Review 2.  Genitourinary long-term outcomes for childhood cancer survivors.

Authors:  Margarett Shnorhavorian; Debra L Friedman; Martin A Koyle
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

Review 3.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

4.  Possible risk of overestimation of renal function using cystatin C-based eGFR in testicular cancer survivors treated with cisplatin-based chemotherapy.

Authors:  Daishi Ichioka; Koji Kawai; Ken Tanaka; Ryutaro Ishitsuka; Takayuki Yoshino; Tomokazu Kimura; Shuya Kandori; Takashi Kawahara; Takahiro Kojima; Joichi Usui; Kunihiro Yamagata; Jun Miyazaki; Hiroyuki Nishiyama
Journal:  Clin Exp Nephrol       Date:  2017-09-25       Impact factor: 2.801

Review 5.  Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.

Authors:  Blessy George; Melanie S Joy; Lauren M Aleksunes
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-12

6.  Investigation of the efficacy of 99 mTc-DTPA scintigraphic GFR measurement with Gates method in the detection of cisplatin-induced nephrotoxicity in comparison with plasma urea and creatinine measurement.

Authors:  Filiz Özülker; Tamer Özülker; Aysun Küçüköz Uzun; Tevfik Özpaçacı
Journal:  Med Oncol       Date:  2010-05-14       Impact factor: 3.064

7.  Cisplatin Induced Renal Insufficiency Measured by Glomerular Filtration Rate with 99mTc-DTPA and by using Serum Creatinine based Formulae: A Prospective Study.

Authors:  Rohini Khurana; Satyawati Deswal; Chandra Prakash; Dhananjay Kumar Singh
Journal:  J Clin Diagn Res       Date:  2016-12-01

8.  Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Authors:  Eve T Rodler; Brenda F Kurland; Melissa Griffin; Julie R Gralow; Peggy Porter; Rosa F Yeh; Vijayakrishna K Gadi; Jamie Guenthoer; Jan H Beumer; Larissa Korde; Sandra Strychor; Brian F Kiesel; Hannah M Linden; John A Thompson; Elizabeth Swisher; Xiaoyu Chai; Stacie Shepherd; Vincent Giranda; Jennifer M Specht
Journal:  Clin Cancer Res       Date:  2016-01-22       Impact factor: 12.531

9.  Long-Term Renal Outcomes after Cisplatin Treatment.

Authors:  Sheron Latcha; Edgar A Jaimes; Sujata Patil; Ilya G Glezerman; Swati Mehta; Carlos D Flombaum
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-12       Impact factor: 8.237

Review 10.  Mechanisms of Cisplatin nephrotoxicity.

Authors:  Ronald P Miller; Raghu K Tadagavadi; Ganesan Ramesh; William Brian Reeves
Journal:  Toxins (Basel)       Date:  2010-10-26       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.